直肠癌术前同步加量放疗可改善降期且不增加毒性:配对分析
该配对分析纳入局部晚期直肠癌患者,比较同步加量放疗(52.5 Gy/5周)与标准剂量放疗(45 Gy)的疗效与安全性。同步加量组肿瘤降期率更高(76% vs 51%),5年局部控制率更高(100% vs 90%),10年无进展生存和总生存也更高,而≥3级放疗相关毒性及手术并发症无显著差异。
要点
- 同步加量放疗组肿瘤降期率显著高于标准剂量组(76% vs 51%,P<.01)。
- 同步加量组5年局部控制率100%,标准剂量组90%(P=.01)。
- 两组≥3级放疗相关毒性及手术并发症无显著差异。
核心结论
- 局部晚期直肠癌术前同步加量放疗安全有效,可改善T降期和局部控制。
研究设计与样本
- 病例对照分析,76例同步加量放疗患者按手术类型、T分期和临床N分期与标准剂量放疗患者配对。
- 同步加量方案为5-氟尿嘧啶联合放疗52.5 Gy/5周,标准剂量方案为5-氟尿嘧啶联合放疗45 Gy。
主要发现
- 同步加量组肿瘤降期率76%,标准剂量组51%(P<.01)。
- 病理完全缓解率两组无差异(同步加量17.1% vs 标准剂量15.8%,P=1.00)。
- ≥3级放疗相关毒性发生率低且相似(同步加量10% vs 标准剂量3%,P=.22)。
- 5年局部控制率同步加量组100.0%,标准剂量组90.0%(P=.01)。
- 10年无进展生存率同步加量组71.9% vs 标准剂量组57.6%(P<.01),总生存率71.6% vs 62.4%(P=.01)。
关键数值与推荐
- 同步加量放疗剂量为52.5 Gy/5周,标准剂量放疗为45 Gy。
- 肿瘤降期率76% vs 51%(P<.01),病理完全缓解率17.1% vs 15.8%(P=1.00)。
- 5年局部控制率100.0% vs 90.0%(P=.01),10年无进展生存率71.9% vs 57.6%(P<.01),10年总生存率71.6% vs 62.4%(P=.01)。
临床怎么用
- 对局部晚期直肠癌患者,术前同步加量放疗可作为安全有效的剂量递增策略。
- 同步加量放疗可提高肿瘤降期和局部控制,且不增加≥3级毒性及手术并发症。
局限性
- 回顾性病例对照分析,非随机对照设计。
- 同步加量组肿瘤距肛缘更近(4.7 vs 5.7 cm,P=.02),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pathologic complete response to neoadjuvant chemoradiation therapy (CRT) is associated with improved outcomes for patients with locally advanced rectal cancer (LARC). Increased response rates have been reported with higher radiation doses, but these studies often lack long-term outcome and/or toxicity data. We conducted a case-control analysis of patients with LARC who underwent definitive CRT to determine the efficacy and safety of intensified treatment with a concomitant boost (CB) approach. METHODS AND MATERIALS: From 1995 to 2003, a phase 2 protocol examined CRT with 5-fluorouracil and CB radiation therapy (52.5 Gy in 5 weeks) for patients with LARC. Seventy-six protocol patients were matched (case-control approach) for surgery type, tumor (T) stage, and clinical nodal (N) stage with patients who received standard dose (SD) CRT (5-fluorouracil, 45 Gy). A chart review was performed. McNemar's test and Kaplan-Meier analyses were used for statistical analysis. RESULTS: The SD and CB groups did not differ in tumor circumferential involvement and length, but the tumors of CB patients were closer to the anal verge (4.7 vs 5.7 cm; P = .02). Although tumor downstaging was higher in the CB cohort (76% vs 51%; P < .01), pathologic complete response rates did not differ (CB, 17.1% vs SD, 15.8%, P = 1.00). The incidence of grade ≥3 radiation-related toxicities was low and similar in both groups (CB, 10% vs SD, 3%, P = .22). Postoperative (anastomotic leak, wound complications/abscess, bleeding) and late (small bowel obstruction, stricture) complication rates did not differ between the groups (P > .05). The median follow-up was 11.9 years. The 5-year local control rates were higher for CB (100.0%) compared with SD (90.0%) patients (P = .01). CB patients had higher rates of 10-year progression-free survival (71.9% vs 57.6%, P < .01) and overall survival (71.6% vs 62.4%, P = .01) compared with SD patients. CONCLUSIONS: CRT dose escalation for patients with LARC is safe and effective. The improved T-downstaging and local control observed in CB patients should encourage further dose escalation studies.
引用
- Gunther JR, Chadha AS, Shin US, et al. Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol. 2017. PMID: 29114614. doi:10.1016/j.adro.2017.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。